Elucidating Structural, Functional and Phylogenetic Relationship of Large Envelope Protein of Hepatitis B V irus

Ruchi Yadav

doi:10.17485/IJST/v15i10.491

Article

Elucidating Structural, Functional and Phylogenetic Relationship of Large Envelope Protein of Hepatitis B V irus

VIEWS 806
PDF 178

Indian Journal of Science and Technology

DOI: 10.17485/IJST/v15i10.491

Year: 2022, Volume: 15, Issue: 10, Pages: 451-456

Original Article

Elucidating Structural, Functional and Phylogenetic Relationship of Large Envelope Protein of Hepatitis B V irus

Ruchi Yadav^1*

¹Amity Institute of Biotechnology, Amity University, Uttar Pradesh Lucknow Campus, 226028

*Corresponding Author
Email: [email protected]

Received Date:22 March 2021, Accepted Date:28 January 2022, Published Date:11 March 2022

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Objectives: To predict the structure of L-HBsAg envelope protein of Hepatitis B Virus and its evolutionary relationship. Methods: Bioinformatics Computational methods were used for the structure prediction and evolutionary conservation analysis of large envelope protein of Hepatitis B virus (L-HBsAg). Structure prediction L-HBsAg envelope protein was done using Multi-template homology modeling method using Schrodinger software. Phylogenetic tree was constructed by MEGA tool to identify protein similarity of L-HBsAg protein with other genotypes of HBV. Findings: Modelled structure of L-HBsAg protein shows that this protein has single alpha-helix and loop structure. Multiple sequence alignment result shows that L-HBsAg belongs to family of vMSA (pfam00695, major surface antigen from hepadnavirus) conserved domain. Phylogenetic tree reveals that L-HBsAg shows similarity with other proteins of HBV protein like preS protein and envelope protein. Novelty: Structural analysis identifies the binding properties of L-HBsAg protein. This study concluded that large envelope protein of HBV can be potent drug target for designing a novel drug.

Keywords: LHBsAg; HBV; evolutionary analysis; structure prediction; dane particles

References

Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. The Lancet. 2018;392(10161):2313–2324. Available from: https://dx.doi.org/10.1016/s0140-6736(18)31865-8
Shih C, Yang CC, Choijilsuren G, Chang CH, Liou AT. Hepatitis B Virus. Trends in Microbiology. 2018;26:386–387. Available from: https://dx.doi.org/10.1016/j.tim.2018.01.009
Hu J, Protzer U, Siddiqui A. Revisiting Hepatitis B Virus: Challenges of Curative Therapies. Journal of Virology. 2019;93(20):1032–1051. Available from: https://dx.doi.org/10.1128/jvi.01032-19
Revill PA, Tu T, Netter HJ, Yuen LKW, Locarnini SA, Littlejohn M. The evolution and clinical impact of hepatitis B virus genome diversity. Nature Reviews Gastroenterology & Hepatology. 2020;17(10):618–634. Available from: https://dx.doi.org/10.1038/s41575-020-0296-6
Ko C, Chakraborty A, Chou WM, Hasreiter J, Wettengel JM, Stadler D, et al. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. Journal of Hepatology. 2018;69(6):1231–1241. Available from: https://dx.doi.org/10.1016/j.jhep.2018.08.012
Hu J, Protzer U, Siddiqui A. Revisiting Hepatitis B Virus: Challenges of Curative Therapies. Journal of Virology. 2019;93(20):1032–1051. Available from: https://dx.doi.org/10.1128/jvi.01032-19
Budzinska MA, Shackel NA, Urban S, Tu T. Cellular Genomic Sites of Hepatitis B Virus DNA Integration. Genes. 2018;9(7):365. Available from: https://dx.doi.org/10.3390/genes9070365
Martinez MG, Villeret F, Testoni B, Zoulim F. Can we cure hepatitis B virus with novel direct‐acting antivirals? Liver International. 2020;40(S1):27–34. Available from: https://dx.doi.org/10.1111/liv.14364
Zhao Q, Hu Z, Cheng J, Wu S, Luo Y, Chang J, et al. Hepatitis B Virus Core Protein Dephosphorylation Occurs during Pregenomic RNA Encapsidation. Journal of Virology. 2018;92(13):2139–2156. Available from: https://dx.doi.org/10.1128/jvi.02139-17
Mak LY, Wong DKH, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Alimentary Pharmacology & Therapeutics. 2018;47:43–54. Available from: https://dx.doi.org/10.1111/apt.14376
Mitra B, Wang J, Kim ES, Mao R, Dong M, Liu Y, et al. Hepatitis B Virus Precore Protein p22 Inhibits Alpha Interferon Signaling by Blocking STAT Nuclear Translocation. Journal of Virology. 2019;93(13):196–215. Available from: https://dx.doi.org/10.1128/jvi.00196-19
Waheed Y, Siddiq M, Jamil Z, Najmi MH. Hepatitis elimination by 2030: Progress and challenges. World Journal of Gastroenterology. 2018;24:4959–4961. Available from: https://dx.doi.org/10.3748/wjg.v24.i44.4959
Caballero A, Tabernero D, Buti M, Rodriguez-Frias F. Hepatitis B virus: The challenge of an ancient virus with multiple faces and a remarkable replication strategy. Antiviral Research. 2018;158:34–44. Available from: https://dx.doi.org/10.1016/j.antiviral.2018.07.019
Gerlich WH, Glebe D, Kramvis A, Magnius LO. Peculiarities in the designations of hepatitis B virus genes, their products, and their antigenic specificities: a potential source of misunderstandings. Virus Genes. 2020;56(2):109–119. Available from: https://dx.doi.org/10.1007/s11262-020-01733-9
Yadav R, Srivastava P. Establishment of resveratrol and its derivatives as neuroprotectant against monocrotophos-induced alteration in NIPBL and POU4F1 protein through molecular docking studies. Environmental Science and Pollution Research. 2020;27(1):291–304. Available from: https://dx.doi.org/10.1007/s11356-019-06806-3
Rajbhar P, Singh D, Fatima R, Yadav R. Evolutionary relationship and repurposing of sars inhibitors against surface glycoprotein of SARS-COV-2. International Journal of Applied Pharmaceutics. 2021;2021:272–279. Available from: https://dx.doi.org/10.22159/ijap.2021v13i5.42652
Yadav R, Srivastava P. Interaction Study of Antioxidants with Progressive Myoclonus Epilepsy by Molecular Docking Techniques. Research Journal of Pharmacy and Technology. 2019;12(2):584. Available from: https://dx.doi.org/10.5958/0974-360x.2019.00104.5
Yadav R, Srivastava P. Interaction Study of Antioxidants with Progressive Myoclonus Epilepsy by Molecular Docking Techniques. Research Journal of Pharmacy and Technology. 2019;12(2):584. Available from: https://dx.doi.org/10.5958/0974-360x.2019.00104.5
Nagy LG, Merényi Z, Hegedüs B, Bálint B. Novel phylogenetic methods are needed for understanding gene function in the era of mega-scale genome sequencing. Nucleic Acids Research. 2020;48(5):2209–2219. Available from: https://dx.doi.org/10.1093/nar/gkz1241

Copyright

© 2022 Yadav. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Published By Indian Society for Education and Environment (iSee)